Mapt<tm1Hnd> Targeted Allele Detail MGI Mouse (MGI:2385630)

Mapt^tm1Hnd
Targeted Allele Detail

Nomenclature

Symbol:	Mapt^tm1Hnd
Name:	microtubule-associated protein tau; targeted mutation 1, Hana N Dawson
MGI ID:	MGI:2385630
Synonyms:	TAU^-
Gene:	Mapt Location: Chr11:104092704-104193404 bp, + strand Genetic Position: Chr11, 64.0 cM, cytoband E1

Mutation
origin

Germline Transmission:	Earliest citation of germline transmission: J:78649
Parent Cell Line:	Not Specified (ES Cell)
Strain of Origin:	Not Specified

Mutation
description

Allele Type:	Targeted (knock-out)
Mutations:	Insertion, Intragenic deletion
	Exon 1, encoding the translational start site, was replaced by a neomycin selection cassette via homologous recombination. RT-PCR analysis of total brain RNA obtained from homozygous mutant mice showed a lack of transcript produced by the targeted locus. The absence of encoded protein was verified by Western blot analysis of brain homogenates as well as by immunocytochemical analysis of coronal sections. (J:78649)

Find Mice (IMSR)

Mouse strains and cell lines available from the International Mouse Strain Resource (IMSR)

Carrying this Mutation:	Mouse Strains: 1 strain available Cell Lines: 0 lines available
Carrying any Mapt Mutation:	386 strains or lines available

Phenotype
summary

Phenotype Summary by Mammalian Phenotype terms

(show or hide all annotated terms)

Genotypes are listed in the next section.

Key:

hm	homozygous	ht	heterozygous
cn	conditional genotype	cx	complex: > 1 genome feature
tg	involves transgenes	ot	other: hemizygous, indeterminate,...
N	normal phenotype		expected model not found

Affected Systems	Genotypes:	hm1	hm2	ht3	tg4	tg5
behavior/neurological			√	√	√	√
behavior/neurological phenotype					N	N
decreased susceptibility to pharmacologically induced seizures			√	√	√	√
abnormal spatial learning						√
		hm1	hm2	ht3	tg4	tg5
nervous system		√	√	√	√	√
decreased susceptibility to pharmacologically induced seizures			√	√	√	√
abnormal neurogenesis					√	√
abnormal axon outgrowth		√
abnormal neuron morphology					√	√
abnormal dendrite morphology		√
amyloid beta deposits					√	√
		hm1	hm2	ht3	tg4	tg5
other phenotype					√	√
amyloid beta deposits					√	√

Phenotypic
data by
genotype

Phenotypic Data by Genotype

(show or hide all phenotypic details)

Genotype	Allelic Composition	Genetic Background
hm1	Mapt^tm1Hnd/Mapt^tm1Hnd	involves: 129X1/SvJ * C57BL/6
nervous system abnormal axon outgrowth (J:78649) neuronal cultures from E16 mice show less axonal extension than wild-type neurons; mutant neurons lag behind wild-type in development over initial 2 days in culture, then catch up, but total sum of minor processes/axonal lengths is less than wild-type abnormal dendrite morphology (J:78649) between 4 and 7 days in culture, total dendritic length of mutant neurons is less than in wild-type; after 7 days in culture, neurons still lag behind wild-type showing more developmental delay
Genotype	Allelic Composition	Genetic Background
hm2	Mapt^tm1Hnd/Mapt^tm1Hnd	involves: C57BL/6
behavior/neurological decreased susceptibility to pharmacologically induced seizures (J:121330) severity is reduced and seizure onset is delayed after pentylenetetrazole treatment compared to wild-type mice mice are resistant to kainate-induced seizures over a larger range of doses than wild-type mice nervous system decreased susceptibility to pharmacologically induced seizures (J:121330) severity is reduced and seizure onset is delayed after pentylenetetrazole treatment compared to wild-type mice mice are resistant to kainate-induced seizures over a larger range of doses than wild-type mice
Genotype	Allelic Composition	Genetic Background
ht3	Mapt^tm1Hnd/Mapt⁺	involves: C57BL/6
behavior/neurological decreased susceptibility to pharmacologically induced seizures (J:121330) severity is reduced and seizure onset is delayed after pentylenetetrazole treatment compared to wild-type mice mice are resistant to kainate-induced seizures over a larger range of doses than wild-type mice nervous system decreased susceptibility to pharmacologically induced seizures (J:121330) severity is reduced and seizure onset is delayed after pentylenetetrazole treatment compared to wild-type mice mice are resistant to kainate-induced seizures over a larger range of doses than wild-type mice
Genotype	Allelic Composition	Genetic Background
tg4	Mapt^tm1Hnd/Mapt^tm1Hnd Tg(PDGFB-APPSwInd)20Lms/0	involves: C57BL/6 * DBA/2
behavior/neurological behavior/neurological phenotype (J:121330) mice show normal spatial learning and object-recongition memory, at levels similar to non-transgenic controls mice show no signs of hyperactivity decreased susceptibility to pharmacologically induced seizures (J:121330) seizures are less severe and occur at longer latencies compared to transgenic mice with wild-type Mapt nervous system decreased susceptibility to pharmacologically induced seizures (J:121330) seizures are less severe and occur at longer latencies compared to transgenic mice with wild-type Mapt abnormal neurogenesis (J:121330) aberrant sprouting of hippocampal axons is observed in transgenic mice abnormal neuron morphology (J:121330) mice show neuritic dystrophy around amyloid plaques amyloid beta deposits (J:121330) at 4-7 months and 14-18 months, Abeta plaque deposition is observed, at levels the same as other transgenics heterozygous or wild-type for Mapt other phenotype amyloid beta deposits (J:121330) at 4-7 months and 14-18 months, Abeta plaque deposition is observed, at levels the same as other transgenics heterozygous or wild-type for Mapt
Genotype	Allelic Composition	Genetic Background
tg5	Mapt^tm1Hnd/Mapt⁺ Tg(PDGFB-APPSwInd)20Lms/0	involves: C57BL/6 * DBA/2
behavior/neurological behavior/neurological phenotype (J:121330) mice show no signs of hyperactivity decreased susceptibility to pharmacologically induced seizures (J:121330) seizures are less severe and occur at longer latencies compared to transgenic mice with wild-type Mapt abnormal spatial learning (J:121330) in the hidden platform version of the Morris water maze, non-trangenic controls, regardless of Mapt genotype learn the task over 3 days, whereas transgenic mice heterozygous for Mapt^tm1Hnd show show impaired learning compared to controls but less impairment than transgenic mice with normal Mapt expression in probe trials where the platform is removed, mice show delayed learning, compared to non transgenic controls or transgenic mice with wild-type Mapt, with more target than non-target crossings after 5 days of training nervous system decreased susceptibility to pharmacologically induced seizures (J:121330) seizures are less severe and occur at longer latencies compared to transgenic mice with wild-type Mapt abnormal neurogenesis (J:121330) aberrant sprouting of hippocampal axons is observed in transgenic mice abnormal neuron morphology (J:121330) mice show neuritic dystrophy around amyloid plaques amyloid beta deposits (J:121330) at 4-7 months and 14-18 months, Abeta plaque deposition is observed, at levels the same as other transgenics null or wild-type for Mapt other phenotype amyloid beta deposits (J:121330) at 4-7 months and 14-18 months, Abeta plaque deposition is observed, at levels the same as other transgenics null or wild-type for Mapt

References

Original:	J:78649 Dawson HN et al., "Inhibition of neuronal maturation in primary hippocampal neurons from tau deficient mice." J Cell Sci 2001 Mar;114(Pt 6):1179-87
All:	8 reference(s)

Contributing Projects: Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Tumor Biology (MTB), Gene Ontology (GO), MouseCyc
Citing These Resources Funding Information Warranty Disclaimer & Copyright Notice Send questions and comments to User Support.	last database update 11/20/2009 MGI_4.31 Web browser compatibility